An evaluation of the cell cycle‐associated monoclonal antibody Ki‐S1 as a prognostic factor in primary invasive adenocarcinoma of the breast | Zendy

Morris E. S. | Zendy; Elston C. W. | Zendy; Bell J. A. | Zendy; Galea M. | Zendy; Blamey R. W. | Zendy; Ellis I. O. | Zendy

Premium

An evaluation of the cell cycle‐associated monoclonal antibody Ki‐S1 as a prognostic factor in primary invasive adenocarcinoma of the breast

Author(s) -

Morris E. S.,

Elston C. W.,

Bell J. A.,

Galea M.,

Blamey R. W.,

Ellis I. O.

Publication year - 1995

Publication title -

the journal of pathology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.964

H-Index - 184

eISSN - 1096-9896

pISSN - 0022-3417

DOI - 10.1002/path.1711760109

Subject(s) - immunohistochemistry , monoclonal antibody , antigen , breast carcinoma , adenocarcinoma , pathology , carcinoma , ki 67 , antibody , mitosis , medicine , biology , oncology , breast cancer , cancer , immunology , microbiology and biotechnology

Immunohistochemical staining with the novel monoclonal antibody Ki‐S1, believed to recognize a cell cycle‐associated antigen, was investigated in 110 cases of invasive carcinoma of the breast. Immunoreactivity indices were compared with disease‐free interval (DFI), overall survival, and a series of other prognostic indicators. Significant positive correlations were found between the percentage of strongly positive immunoreactive nuclei and tumour size, histological grade and type, vascular invasion, and mitotic count. A significant negative correlation was found with age. No significant correlation was found with either DFI or overall survival. Although a correlation with mitotic count does imply that the Ki‐S1 antigen is cell cycle‐associated to some extent, Ki‐S1 does not appear to be a useful prognostic factor in human breast carcinoma.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research